^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CS1002 (ipilimumab biosimilar)

i
Other names: CS1002, CS-1002, CS 1002, SHR-8068, SHR8068, SHR 8068
Company:
CStone Pharma, Jiangsu Hengrui Pharma
Drug class:
CTLA4 inhibitor
14d
New P1/2 trial
|
Avastin (bevacizumab) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • NKT2152
16d
Enrollment open
|
Tevimbra (tislelizumab-jsgr) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
17d
New P3 trial
|
cisplatin • Imfinzi (durvalumab) • gemcitabine • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
2ms
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer (clinicaltrials.gov)
P2, N=200, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
trastuzumab rezetecan (SHR-A1811) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • garetatug rezetecan (SHR-A1904)
3ms
New P3 trial
|
Tevimbra (tislelizumab-jsgr) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
3ms
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer (clinicaltrials.gov)
P2, N=153, Active, not recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting | N=240 --> 153 | Trial primary completion date: Jun 2025 --> Dec 2025
Enrollment closed • Enrollment change • Trial primary completion date
|
cisplatin • paclitaxel • capecitabine • oxaliplatin • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
4ms
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer (clinicaltrials.gov)
P2, N=200, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
Avastin (bevacizumab) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
4ms
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov)
P2, N=120, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
cisplatin • carboplatin • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
4ms
New P2 trial
|
trastuzumab rezetecan (SHR-A1811) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • garetatug rezetecan (SHR-A1904)
5ms
New P2 trial
|
Avastin (bevacizumab) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
6ms
New P2 trial
|
cisplatin • carboplatin • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
6ms
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
P1/2, N=100, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
Avastin (bevacizumab) • cisplatin • carboplatin • trastuzumab rezetecan (SHR-A1811) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)